VERU — VERU INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 863894 ·
Last close
$2.59
Market Cap
$44.16M
52W High
$7.33
52W Low
$2.11
ADV30
257,700
Next earnings
2026-08-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -7,218,968 | -2,741,132 | 43,082,726 | 27,596,820 | 8,297,105 |
| Dec 2025 | 0 | — | -5,424,015 | -5,332,579 | 47,567,030 | 32,991,417 | 10,442,989 |
| Sep 2025 | 0 | — | -7,459,363 | 1,453,507 | 29,835,719 | 15,794,562 | 11,503,049 |
| Jun 2025 | 0 | — | -8,031,091 | -7,332,820 | 27,330,758 | 15,010,154 | 11,986,125 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-26,058,053
Investing CF
$10,270,136
Financing CF
$23,366,345
CapEx
$-1,083
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.38
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-325,369,625
Inventory
—
Receivables
—
ST Investments
$3,167,733
EBIT TTM
$-28,133,437
Pretax Income TTM
$-14,444,090
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | -35,530,932 | -22,726,279 | 29,835,719 | 11,503,049 | — | -30,043,088 |
| Sep 2024 | 0 | -37,391,968 | -37,801,426 | 60,418,772 | 28,102,060 | — | -21,682,333 |
| Sep 2023 | 16,296,958 | -95,605,839 | -93,152,692 | 50,023,091 | 30,344,930 | — | -88,013,814 |
| Sep 2022 | 39,354,352 | -83,488,158 | -84,040,618 | 135,358,450 | 52,561,133 | — | -47,505,004 |
| Sep 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$36,351,548
NetIncome TTM
$-97,386,373
OpCashFlow TTM
$0
Assets (Latest)
$70,337,351
Forward EPS
$-0.98
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FLNA | FILANA THERAPEUTICS, INC. | $44.93M | $0.93 | — |
| IXHL | Incannex Healthcare Inc. | $43.31M | $3.62 | — |
| HOWL | Werewolf Therapeutics, Inc. | $42.93M | $0.88 | — |
| CNTX | Context Therapeutics Inc. | $42.76M | $0.47 | — |
| GRCE | Grace Therapeutics, Inc. | $45.86M | $2.18 | — |
News headlines (Yahoo Finance, 1h cache)
Veru (VERU) Q3 2026 Earnings Call Transcript
2026-08-17 11:58 · Yahoo
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
2026-08-04 12:30 · Yahoo
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
2026-07-30 12:30 · Yahoo
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
2026-07-27 12:10 · Yahoo
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
2026-07-07 12:30 · Yahoo
Veru And 2 Other Intriguing Penny Stocks To Watch
2026-06-05 12:05 · Yahoo
Novo Nordisk Tests Wegovy Combinations In Older Adults With Veru Trial
2026-06-05 06:09 · Yahoo
This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection?
2026-06-04 17:16 · Yahoo
Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU)
2026-06-04 14:22 · Yahoo
Earnings call transcript: Veru Inc Q2 2026 shows improved financials
2026-06-01 04:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.